Contraception
Volume 82, Issue 2 , Pages 160-167 , August 2010

Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial

  • Carla Picardo

      Affiliations

    • Department of Social Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    • Corresponding Author InformationCorresponding author. 2315 Myrtle Street, Erie, PA 16502, USA. Tel.: +1 814 454 8185; fax: +1 814 454 3894.
    • ,
  • Stefanie Ferreri

      Affiliations

    • University of North Carolina School of Pharmacy, Chapel Hill, NC, USA

Received 11 August 2009 ,Revised 10 January 2010 ,Accepted 13 January 2010.

References 

  1. Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health. 1998;23:81–88
  2. Potter LS, Dalberth BT, Canamar R, Betz M. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Contraception. 1997;56:305–312
  3. Sangi-Haghpeykar H, Poindexter AN, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88:227–233
  4. Westfall JM, Main DS, Barnard L. Continuation rates among injectable contraceptive users. Fam Plann Perspect. 1996;28:275–277
  5. O'Dell CM, Forke CM, Polaneczky MM, Sondheimer SJ, Slap GB. Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol. 1998;91:609–614
  6. Polaneczky M, Guarnaccia M, Alon J, Wiley J. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population. Fam Plann Perspect. 1996;28:174–178
  7. Davidson AR, Kalmuss D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am J Public Health. 1997;87:1532–1534
  8. Steyer TE, Ragucci KR, Pearson WS, Mainous AG. The role of pharmacists in the delivery of influenza vaccinations. Vaccine. 2004;22:1001–1006
  9. Picardo C. Pharmacist-administered depot medroxyprogesterone acetate. Contraception. 2006;73:559–561
  10. Landau SC, Tapias MD, McGhee BT. Birth control within reach: a national survey on women's attitudes toward and interest in pharmacy access to hormonal contraception. Contraception. 2006;74:463–470
  11. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194
  12. Schultz K, Grimes D. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359:614–618
  13. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception. 2006;74:234–238
  14. Westhoff C, Jain JK, Milson I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007;75:261–267
  15. Omar H, Fowler A, D'Angelo S. Improved continuation rate of depot-medroxyprogesterone acetate in adolescent mothers. Int J Adolesc Med Health. 2002;14:149–152
  16. Gardner JS, Miller L, Downing DF, Le S, Blough D, Shotorbani S. Pharmacist prescribing of hormonal contraceptives: results of the Direct Access study. J Am Pharm Assoc. 2008;48:212–221

☆ Funding for this study was from (1) Pfizer, Inc., from an investigator-initiated grant and supply of DMPA-SC and (2) an Epidemiology and Clinical Trials training grant for Dr. Picardo from the National Institute of Child Health and Human Development.

PII: S0010-7824(10)00014-4

doi: 10.1016/j.contraception.2010.01.013

Contraception
Volume 82, Issue 2 , Pages 160-167 , August 2010

Article Tools

* Image Usage & Resolution